Article | April 1, 2020

Centralized IBC Review Benefits On Research

Source: Advarra

By Daniel Eisenman, Director of Biosafety Services

gene therapy

The gene therapy field is experiencing explosive growth in today’s competitive research environment. Gene therapy entails the transfer of engineered genetic materials to human research subjects. These studies were previously considered to be highly experimental and limited to early phase trials at a handful of highly specialized academic medical centers. However, well-established safety profiles, promising research results, and the FDA issuing the first gene therapy approvals in recent years have led to dramatic growth.

Searching clinicaltrials.gov for gene therapy studies results in 4070 hits with 1067 studies currently recruiting or enrolling research subjects. As of September 2019, 295 phase III studies are listed, representing a growing pipeline of gene therapy products are preparing to undergo consideration for FDA approval.

This blog summarizes the growth, risks, and regulatory requirements for gene therapy research.

  • Risks and regulatory requirements
  • Efficiencies from a centralized review

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: